{"id":"mifegyne","safety":{"commonSideEffects":[{"rate":"~100","effect":"Vaginal bleeding"},{"rate":"~80","effect":"Abdominal pain/cramping"},{"rate":"~60","effect":"Nausea"},{"rate":"~40","effect":"Diarrhea"},{"rate":"~30","effect":"Headache"},{"rate":"~20","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1276308","moleculeType":"Small molecule","molecularWeight":"429.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mifepristone competitively binds to progesterone receptors in the uterus and other tissues, blocking the effects of endogenous progesterone. This leads to detachment of the blastocyst or embryo from the uterine wall and, when combined with a prostaglandin analog, results in expulsion of pregnancy tissue. It is also used to manage conditions where progesterone excess is pathological.","oneSentence":"Mifepristone is a progesterone receptor antagonist that blocks progesterone signaling to induce abortion or manage progesterone-dependent conditions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:58.516Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Medical abortion (termination of early pregnancy up to 49 days gestation)"},{"name":"Cushing's syndrome (progesterone-dependent conditions)"}]},"trialDetails":[{"nctId":"NCT02788981","phase":"PHASE2","title":"Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2017-03-28","conditions":"Breast Cancer","enrollment":29},{"nctId":"NCT05772169","phase":"PHASE4","title":"Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2023-03-31","conditions":"Hypercortisolism, Diabetes Mellitus, Type 2","enrollment":1113},{"nctId":"NCT03659045","phase":"NA","title":"Pain Assessment in MToP Up to 7 WA (during 5h After Misoprostol Intake)","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-01-15","conditions":"Abortion-Related Disorders","enrollment":320},{"nctId":"NCT04588688","phase":"PHASE2","title":"Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency","status":"TERMINATED","sponsor":"Tobias Else","startDate":"2021-05-05","conditions":"Central Adrenal Insufficiency, Mifepristone","enrollment":3},{"nctId":"NCT03320057","phase":"PHASE4","title":"Medication Abortion Via Pharmacy Dispensing","status":"COMPLETED","sponsor":"Daniel Grossman","startDate":"2018-06-01","conditions":"Pregnancy Related, Abortion Early","enrollment":326},{"nctId":"NCT02642939","phase":"PHASE2","title":"Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Check, Jerome H., M.D., Ph.D.","startDate":"2015-12","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":3},{"nctId":"NCT03829696","phase":"PHASE4","title":"Advance Provision of Medication Abortion","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2020-01","conditions":"Early Abortion","enrollment":""},{"nctId":"NCT02014337","phase":"PHASE1","title":"Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2014-01","conditions":"Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma","enrollment":37},{"nctId":"NCT01795599","phase":"PHASE3","title":"Cervical Preparation for Surgical Abortion at 12-14 Weeks: a Prospective, Randomized, Evaluator-blinded, Multicenter, Controlled Comparison Between Mifepristone, Misoprostol and Their Combination","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2013-05","conditions":"Surgical Abortion","enrollment":198},{"nctId":"NCT00936741","phase":"PHASE3","title":"An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2009-07","conditions":"Cushing's Syndrome","enrollment":30},{"nctId":"NCT01371565","phase":"PHASE3","title":"Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2010-11","conditions":"Cushing's Disease, Cushing's Syndrome","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mifegyne ®","genericName":"Mifegyne ®","companyName":"Assistance Publique Hopitaux De Marseille","companyId":"assistance-publique-hopitaux-de-marseille","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mifegyne (Mifepristone) is a small molecule that acts as a glucocorticoid receptor antagonist. It has been studied in various clinical trials for conditions such as breast cancer, surgical abortion, and Cushing's syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}